A team led by Cabezas‑Caballero described engineered co‑signaling receptors that improve T‑cell precision and reduce off‑target cross‑reactivity. The platform pairs antigen recognition with bespoke co‑signaling modules to sharpen activation thresholds and limit unintended responses against healthy tissues. The study presents functional data on reduced cross‑reactivity in engineered T cells and suggests a route to safer adoptive cell therapies by integrating synthetic co‑signaling logic. Clarification: co‑signaling receptors modulate T‑cell activation by delivering auxiliary stimulatory or inhibitory signals alongside the antigen receptor.